Company DiaMedica Inc. Toronto S.E.

Equities

DMA

CA25253T1075

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

Apr. 17	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT
Apr. 17	DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	CI

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Managers	Title	Age	Since
Rick Pauls CEO	Chief Executive Officer	52	05-03-31
Scott Kellen DFI	Director of Finance/CFO	59	18-03-31
Ambarish Shah CTO	Chief Tech/Sci/R&D Officer	-	23-04-30
Lorianne K. Masuoka CTO	Chief Tech/Sci/R&D Officer	62	Jan. 21
James Parsons BRD	Director/Board Member	58	10-10-19
Paul Papi IRO	Public Communications Contact	-	16-11-30
Julie VanOrsdel Daves PRN	Corporate Officer/Principal	-	-
Dominic Cundari PRN	Corporate Officer/Principal	-	22-01-31
David Wambeke PRN	Corporate Officer/Principal	-	23-04-10

Members of the board	Title	Age	Since
Richard Kuntz BRD	Director/Board Member	66	23-05-29
Tanya Lewis BRD	Director/Board Member	53	23-02-28
James Parsons BRD	Director/Board Member	58	10-10-19
Michael Giuffre BRD	Director/Board Member	68	10-08-09
Rick Pauls CEO	Chief Executive Officer	52	05-03-31
Richard Pilnik CHM	Chairman	67	09-04-30
Charles Semba BRD	Director/Board Member	64	21-07-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,958,000	23,517,237 ( 61.96 %)	0	61.96 %

Name	Equities	%	Valuation
Rich Jacinto 12.01 %	4,558,823	12.01 %	13 M $
TomEnterprise AB 11.40 %	4,326,435	11.40 %	12 M $
Trill AB 10.59 %	4,021,608	10.59 %	11 M $
Omega Advisors, Inc. 2.328 %	883,623	2.328 %	2 M $
Vanguard Global Advisers LLC 2.113 %	802,171	2.113 %	2 M $
David Wambeke 1.389 %	527,114	1.389 %	1 M $
Paragon Associates 1.317 %	500,000	1.317 %	1 M $
Michael Giuffre 0.8507 %	322,893	0.8507 %	894 414 $
Altium Capital Management LP 0.7579 %	287,698	0.7579 %	796 923 $
Bleichroeder LP 0.5857 %	222,317	0.5857 %	615 818 $

Name	Equities	%	Valuation
Michael Giuffre -	278,282	-	770 841 $
Richard Pilnik -	119,327	-	330 536 $
Amy Burroughs -	56,132	-	155 486 $
James Parsons -	38,509	-	106 670 $
Rick Pauls -	35,804	-	99 177 $
Scott Kellen -	22,290	-	61 743 $

DiaMedica Therapeutics, Inc.

301 Carlson Parkway Suite 210

55305, Minneapolis

http://www.diamedica.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.58%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-10.21%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs